Jason M. Schenkel
@jmschenkel.bsky.social
T cell immunologist. Transfusion med doc. Assistant Professor in Lab Medicine, Immunology, and TMP @mdanderson.bsky.social
Reposted by Jason M. Schenkel
With deep gratitude, we thank Dr. Marc Jenkins for his decades of leadership, mentorship, and dedication to the Center for Immunology. The foundation he built will guide and inspire us for years to come.
August 25, 2025 at 12:06 PM
With deep gratitude, we thank Dr. Marc Jenkins for his decades of leadership, mentorship, and dedication to the Center for Immunology. The foundation he built will guide and inspire us for years to come.
Fantastic new paper looking at the extrinsic effects of PD-1 loss! Check it out.
@kepauken.bsky.social, Markson, Sharpe et al. @harvardmed.bsky.social show that when PD-1–expressing and PD-1 knockout CD8+ T cells are within the same tumor microenvironment, both cell types exhibit similarly enhanced functions. rupress.org/jem/article/...
July 24, 2025 at 5:23 PM
Fantastic new paper looking at the extrinsic effects of PD-1 loss! Check it out.
Reposted by Jason M. Schenkel
Congratulations to the 2025 Sabin Family Fellowship recipients, 10 early career researchers recognized for their bold, high-impact cancer research.
Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. http://spr.ly/633254IbgR #EndCancer
Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. http://spr.ly/633254IbgR #EndCancer
MD Anderson announces 10th cohort of Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center today announced its 10th cohort of Andrew Sabin Family Fellows, comprised of 10 early career cancer researchers. Created to provide a dedicated source of funding for emerging clinician and scientist leaders, the Sabin Family Fellowship supports groundbreaking research that fuels MD Anderson’s mission to end cancer.
spr.ly
July 11, 2025 at 1:23 PM
Congratulations to the 2025 Sabin Family Fellowship recipients, 10 early career researchers recognized for their bold, high-impact cancer research.
Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. http://spr.ly/633254IbgR #EndCancer
Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. http://spr.ly/633254IbgR #EndCancer
Reposted by Jason M. Schenkel
I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
Secretion of ligands of the human epidermal growth factor (EGFR) family of receptors or erythroblastic leukemia viral oncogene family (ERBB1-4) is a feature common to many cancer cells. However, our u...
www.biorxiv.org
May 9, 2025 at 8:16 PM
I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by Jason M. Schenkel
Kicking off our journey on BlueSky! We're excited to share updates and connect with you. Follow us and help us get the word out! For more information about the Center for Immunology, go to our website: immunology.umn.edu
Center for Immunology
immunology.umn.edu
April 2, 2025 at 6:47 PM
Kicking off our journey on BlueSky! We're excited to share updates and connect with you. Follow us and help us get the word out! For more information about the Center for Immunology, go to our website: immunology.umn.edu
Reposted by Jason M. Schenkel
Excited to share this preprint: In trial led by @michaelpelusomd.bsky.social and Steve Deeks, combination immunotherapy=>high rate of HIV control (low VL) after ART pause. @demisandel.bsky.social in our lab found control associated with robust CD8+ T cell proliferation early in response to rebound.
March 20, 2025 at 6:06 PM
Excited to share this preprint: In trial led by @michaelpelusomd.bsky.social and Steve Deeks, combination immunotherapy=>high rate of HIV control (low VL) after ART pause. @demisandel.bsky.social in our lab found control associated with robust CD8+ T cell proliferation early in response to rebound.
Reposted by Jason M. Schenkel
Different injection routes and fluorophores affect anti-CD45.2 antibody leukocyte labeling @jmschenkel.bsky.social @jimmunol.bsky.social @thenatcat.bsky.social
doi.org/10.1093/jimm...
doi.org/10.1093/jimm...
March 13, 2025 at 2:55 AM
Different injection routes and fluorophores affect anti-CD45.2 antibody leukocyte labeling @jmschenkel.bsky.social @jimmunol.bsky.social @thenatcat.bsky.social
doi.org/10.1093/jimm...
doi.org/10.1093/jimm...
I am pleased to announce that our newest story is officially out at @jimmunol.bsky.social ! academic.oup.com/jimmunol/adv...
This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n
This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n
March 10, 2025 at 11:00 AM
I am pleased to announce that our newest story is officially out at @jimmunol.bsky.social ! academic.oup.com/jimmunol/adv...
This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n
This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n
Reposted by Jason M. Schenkel
Our newest article is online @naturecancer.bsky.social A new antibody drug conjugate that doesn’t kill tumor cells but rely on immune system to eradicate cancer. @bettykimmdphd.bsky.social @mdanderson.bsky.social
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Nature Cancer - Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
www.nature.com
February 25, 2025 at 1:43 PM
Our newest article is online @naturecancer.bsky.social A new antibody drug conjugate that doesn’t kill tumor cells but rely on immune system to eradicate cancer. @bettykimmdphd.bsky.social @mdanderson.bsky.social
Reposted by Jason M. Schenkel
My last editorial in @ImmunoHorizons the little @immunologyaai.bsky.social journal that could. In this commentary I discuss some of the challenges facing academia.
academic.oup.com/immunohorizo...
academic.oup.com/immunohorizo...
Give the grant-writing monkeys another banana
You’re probably familiar with the concept that if you had a million monkeys typing on a million computers for a million years, you would eventually get Sha
academic.oup.com
January 24, 2025 at 10:05 PM
My last editorial in @ImmunoHorizons the little @immunologyaai.bsky.social journal that could. In this commentary I discuss some of the challenges facing academia.
academic.oup.com/immunohorizo...
academic.oup.com/immunohorizo...
Reposted by Jason M. Schenkel
Super excited to announce that the Joag Lab will officially open at @UW, @SCRI in March 2025! We will study the interplay between memory T cells and stromal, humoral, and innate immunity in mucosal tissues. researcherprofiles.seattlechildrens.org/Vineet.Joag. Hiring a technician and a postdoc!
January 22, 2025 at 6:14 PM
Super excited to announce that the Joag Lab will officially open at @UW, @SCRI in March 2025! We will study the interplay between memory T cells and stromal, humoral, and innate immunity in mucosal tissues. researcherprofiles.seattlechildrens.org/Vineet.Joag. Hiring a technician and a postdoc!
39 rotations around the sun! And what a year it's been. The lab has doubled in size. We had our first (3!!!) graduate students and post docs join the lab. We had both our first and second lab papers EVER accepted - the first is out in print... so check it out -(journals.aai.org/jimmunol/art...).
Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer
Key Points. IV anti-CD45.2 label lasts for 3 days and tracks leukocyte migration to tissue.There is continuous innate and adaptive leukocyte migration in a
journals.aai.org
December 22, 2024 at 10:38 PM
39 rotations around the sun! And what a year it's been. The lab has doubled in size. We had our first (3!!!) graduate students and post docs join the lab. We had both our first and second lab papers EVER accepted - the first is out in print... so check it out -(journals.aai.org/jimmunol/art...).
Attention physician scientists! Are you interested in applying for a K08? Of course you are! I will be part of a NIH broadcasted information session featuring myself and another K08 awardee, as well as a reviewer from a K08 study section in January. See the attached flyer! And please repost!
December 17, 2024 at 4:08 AM
Attention physician scientists! Are you interested in applying for a K08? Of course you are! I will be part of a NIH broadcasted information session featuring myself and another K08 awardee, as well as a reviewer from a K08 study section in January. See the attached flyer! And please repost!
Reposted by Jason M. Schenkel
Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9
December 6, 2024 at 10:38 PM
Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9
Reposted by Jason M. Schenkel
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 25, 2024 at 8:43 PM
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang